CLINICAL TRIAL: RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE II TRIAL OF CTLA4IG

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这个项目的目的是测试在环磷酰胺和硫唑嘌呤的24周诱导方案中加入阿巴西普是否可以比单独使用环磷酰胺和硫唑嘌呤更频繁地诱导缓解。次要目标是确定该制剂的安全性、停用免疫抑制药物时的反应持久性和部分应答率。最后，第三个次要目标是确定与单独使用环磷酰胺治疗相比，阿巴特塞特是否能够对疫苗产生更大的反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project is designed to test whether addition of Abatacept to a 24-week induction protocol involving cyclophosphamide followed in turn by azathioprine can induce remission with greater frequency than treatment with cyclophosphamide and azathioprine alone. Secondary objectives are to determine the safety of the agent, the durability of the response when the immunosuppressive medications are stopped and the partial response rate. Finally, a third secondary objective is to ascertain whether the Abatacept enables greater response to vaccinations compared to therapy with cyclophosphamide alone.